NV-387 Oral Gummies Progress in Combating Ebola Outbreak

NanoViricides, Inc., a leader in antiviral drug development, announces significant progress in the Phase IIA clinical trial of its NV-387 Oral Gummies as a treatment for Ebola Bundibugyo virus. With Ebola cases spreading across Africa, particularly affecting the Democratic Republic of Congo (DRC), the company emphasizes the crucial role of this oral drug. Phase IIA is evaluating dosing regimens in 20 patients, aiming for a 28-day survival endpoint.

The trial could soon transition to Phase IIB, marking a pivotal moment in response efforts. Currently, Ebola cases have surfaced in Kenya and Nigeria, amplifying global concerns of transmission. Despite travel restrictions, cases linked to single infected individuals, or "superspreaders," have increased.

Moreover, ongoing vaccine and antibody infusion trials, including the Tumaini vaccine trial and the PARTNERS clinical trial, underscore a comprehensive fight against this epidemic. However, the absence of approved treatments for Ebola BDBV highlights NV-387's potential significance.